Jeffrey A Bluestone Selected Research

Autoimmune Diseases (Autoimmune Disease)

7/2021	Immunotherapy: Building a bridge to a cure for type 1 diabetes.
1/2020	CRISPR screen in regulatory T cells reveals modulators of Foxp3.
1/2020	New Frontiers in the Treatment of Type 1 Diabetes.
1/2020	Treg cell-based therapies: challenges and perspectives.
1/2019	An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
1/2019	Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus.
12/2018	Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier.
12/2018	The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy.
10/2018	Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy.
1/2018	Revisiting IL-2: Biology and therapeutic prospects.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey A Bluestone Research Topics

Disease

56	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 07/2021 - 05/2002
44	Autoimmune Diseases (Autoimmune Disease) 07/2021 - 05/2002
30	Neoplasms (Cancer) 01/2021 - 07/2002
9	Inflammation (Inflammations) 07/2021 - 04/2005
9	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2021 - 10/2004
8	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2018 - 01/2002
4	Infections 10/2018 - 07/2010
3	Immune System Diseases (Immune Disorders) 01/2020 - 01/2005
3	Peripheral Nervous System Diseases (PNS Diseases) 09/2013 - 11/2005
3	Hypersensitivity (Allergy) 11/2010 - 06/2003
2	COVID-19 01/2022 - 07/2020
2	Disease Progression 01/2019 - 04/2005
2	Colitis 10/2018 - 09/2007
2	Melanoma (Melanoma, Malignant) 01/2018 - 07/2010
2	Hyperglycemia 08/2013 - 05/2002
1	Bronchiolitis Obliterans 12/2022
1	Type 2 Diabetes Mellitus (MODY) 01/2022
1	Viremia 01/2022
1	Myocarditis (Carditis) 01/2021
1	Nausea 01/2021
1	Cardiotoxicity 01/2021
1	Neoplasm Metastasis (Metastasis) 10/2020
1	Nervous System Diseases (Neurological Disorders) 01/2020
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2019
1	X-Linked Syndrome Enteropathy Polyendocrinopathy Immune Dysregulation 01/2019
1	Skin Diseases (Skin Disease) 01/2019
1	Basal Cell Carcinoma (Rodent Ulcer) 01/2018
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2018
1	Merkel Cell Carcinoma 01/2018
1	Skin Neoplasms (Skin Cancer) 01/2018
1	Lysosomal Storage Diseases (Lysosomal Storage Disease) 02/2016
1	Rare Diseases (Rare Disease) 02/2016
1	Tetanus 01/2016
1	Primary Immunodeficiency Diseases 08/2015
1	Obesity 07/2015
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2015
1	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2015

Drug/Important Bio-Agent (IBA)

17	Insulin (Novolin)FDA Link 07/2021 - 05/2002
11	AntigensIBA 01/2018 - 01/2002
9	Interleukin-2 (IL2)IBA 01/2021 - 11/2005
9	Monoclonal AntibodiesIBA 01/2019 - 05/2002
8	CytokinesIBA 01/2021 - 07/2002
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2005
6	teplizumabIBA 01/2019 - 05/2002
5	AntibodiesIBA 01/2022 - 09/2003
5	C-PeptideIBA 01/2021 - 03/2004
5	AutoantigensIBA 01/2017 - 05/2006
4	Chimeric Antigen ReceptorsIBA 01/2021 - 10/2015
4	Interleukin-10 (Interleukin 10)IBA 10/2014 - 02/2003
4	Peptides (Polypeptides)IBA 07/2010 - 11/2003
3	Interleukin-6 (Interleukin 6)IBA 01/2020 - 02/2003
3	Biomarkers (Surrogate Marker)IBA 01/2018 - 07/2006
3	Pharmaceutical PreparationsIBA 04/2017 - 09/2005
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2017 - 03/2009
3	MicroRNAs (MicroRNA)IBA 08/2013 - 05/2010
3	Transforming Growth Factor beta (TGF-beta)IBA 09/2007 - 09/2003
2	Imatinib Mesylate (Gleevec)FDA Link 01/2021 - 04/2017
2	cyclopropapyrroloindoleIBA 01/2021 - 12/2018
2	AutoantibodiesIBA 01/2021 - 01/2005
2	Interleukin-17 (Interleukin 17)IBA 01/2019 - 01/2014
2	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 08/2013
2	Tyrosine Kinase InhibitorsIBA 04/2017 - 12/2008
2	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2016 - 12/2013
2	thymoglobulin FDA Link 01/2016 - 12/2013
2	Interleukin-5 (Interleukin 5)IBA 12/2014 - 02/2003
2	InterferonsIBA 10/2014 - 01/2014
2	B7-2 AntigenIBA 09/2013 - 11/2005
2	LigandsIBA 02/2013 - 11/2009
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 12/2022
1	ChromatinIBA 12/2022
1	Abatacept (Orencia)FDA Link 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2021
1	B7-H1 AntigenIBA 01/2021
1	Neoplasm Antigens (Tumor Antigens)IBA 10/2020
1	Membrane Proteins (Integral Membrane Proteins)IBA 07/2020
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2020
1	Transcription Factors (Transcription Factor)IBA 01/2020
1	Fc Receptors (Fc Receptor)IBA 01/2019
1	MethyltransferasesIBA 12/2018
1	Histones (Histone)IBA 12/2018
1	Enhancer of Zeste Homolog 2 ProteinIBA 12/2018
1	ChemokinesIBA 01/2018
1	Ribonucleases (Ribonuclease)IBA 04/2017
1	HLA Antigens (Human Leukocyte Antigens)IBA 03/2017
1	VaccinesIBA 01/2016
1	NucleotidesIBA 08/2015
1	Interleukin-33IBA 07/2015
1	Dystroglycans (Dystroglycan)IBA 01/2015
1	DystrophinIBA 01/2015

Therapy/Procedure

40	Therapeutics 07/2021 - 07/2002
20	Immunotherapy 07/2021 - 10/2002
8	Transplantation 01/2020 - 07/2002
3	Organ Transplantation 12/2018 - 11/2010
2	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2021 - 01/2018
1	Glycemic Control 01/2020
1	Tissue Transplantation 12/2018
1	Precision Medicine 11/2017
1	Drug Therapy (Chemotherapy) 01/2017
1	Enzyme Replacement Therapy 02/2016